|
gptkbp:instanceOf
|
monoclonal antibody
|
|
gptkbp:analyzes
|
submitted
|
|
gptkbp:barrelLength
|
high
|
|
gptkbp:clinicalTrials
|
Phase 1
multiple sites
Phase 1/2
not yet published
NCTXXXXXXX
|
|
gptkbp:collaborations
|
clinical research organizations
|
|
gptkbp:community_service
|
overall survival
|
|
gptkbp:compatibleWith
|
T-cell activation
|
|
gptkbp:competitors
|
other PD-1 inhibitors
|
|
gptkbp:currentStatus
|
completed
|
|
gptkbp:customerFeedback
|
to be collected
|
|
gptkbp:developedBy
|
gptkb:Xencor
|
|
gptkbp:dosageForm
|
every 2 weeks
|
|
gptkbp:drugInterdiction
|
under study
|
|
gptkbp:environmentalConcerns
|
in progress
|
|
gptkbp:firstMatch
|
2020
|
|
gptkbp:hasPopulation
|
advanced cancer patients
|
|
gptkbp:hasVariants
|
with other immunotherapies
|
|
gptkbp:healthcare
|
varied
|
|
gptkbp:historicalResearch
|
expansion studies
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
XmAb18060
|
|
gptkbp:mandates
|
cancer
|
|
gptkbp:market
|
high
|
|
gptkbp:origin
|
humanized
|
|
gptkbp:patentStatus
|
patented
|
|
gptkbp:productionCompany
|
early clinical development
|
|
gptkbp:regulatoryCompliance
|
not approved yet
|
|
gptkbp:relatedEvent
|
ongoing
|
|
gptkbp:relatedTo
|
immune system
|
|
gptkbp:research
|
secured
|
|
gptkbp:research_areas
|
immuno-oncology
monoclonal antibodies
|
|
gptkbp:researchAndDevelopment
|
pending
|
|
gptkbp:researchFocus
|
oncology
|
|
gptkbp:researchInterest
|
ongoing
pharmaceutical companies
improve patient outcomes
forthcoming
various academic centers
|
|
gptkbp:route
|
intravenous
|
|
gptkbp:safetyFeatures
|
in place
under evaluation
|
|
gptkbp:sideEffect
|
immune-related adverse events
|
|
gptkbp:sponsor
|
gptkb:Xencor,_Inc.
|
|
gptkbp:status
|
investigational
|
|
gptkbp:targets
|
solid tumors
PD-1
|
|
gptkbp:triggerType
|
immune checkpoint inhibition
blocks PD-1 receptor
|
|
gptkbp:type
|
IgG1
|